1. Home
  2. BDTX vs JJSF Comparison

BDTX vs JJSF Comparison

Compare BDTX & JJSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDTX
  • JJSF
  • Stock Information
  • Founded
  • BDTX 2014
  • JJSF 1971
  • Country
  • BDTX United States
  • JJSF United States
  • Employees
  • BDTX N/A
  • JJSF N/A
  • Industry
  • BDTX Biotechnology: Biological Products (No Diagnostic Substances)
  • JJSF Specialty Foods
  • Sector
  • BDTX Health Care
  • JJSF Consumer Staples
  • Exchange
  • BDTX Nasdaq
  • JJSF Nasdaq
  • Market Cap
  • BDTX 132.5M
  • JJSF N/A
  • IPO Year
  • BDTX 2020
  • JJSF N/A
  • Fundamental
  • Price
  • BDTX $2.95
  • JJSF $113.50
  • Analyst Decision
  • BDTX Strong Buy
  • JJSF Buy
  • Analyst Count
  • BDTX 6
  • JJSF 2
  • Target Price
  • BDTX $14.83
  • JJSF $142.50
  • AVG Volume (30 Days)
  • BDTX 1.2M
  • JJSF 181.8K
  • Earning Date
  • BDTX 08-05-2025
  • JJSF 08-05-2025
  • Dividend Yield
  • BDTX N/A
  • JJSF 2.74%
  • EPS Growth
  • BDTX N/A
  • JJSF N/A
  • EPS
  • BDTX 0.09
  • JJSF 3.89
  • Revenue
  • BDTX $70,000,000.00
  • JJSF $1,585,410,000.00
  • Revenue This Year
  • BDTX N/A
  • JJSF $3.64
  • Revenue Next Year
  • BDTX N/A
  • JJSF $3.68
  • P/E Ratio
  • BDTX $33.54
  • JJSF $29.29
  • Revenue Growth
  • BDTX N/A
  • JJSF 0.49
  • 52 Week Low
  • BDTX $1.20
  • JJSF $109.71
  • 52 Week High
  • BDTX $6.75
  • JJSF $180.80
  • Technical
  • Relative Strength Index (RSI)
  • BDTX 71.02
  • JJSF 43.79
  • Support Level
  • BDTX $2.43
  • JJSF $115.10
  • Resistance Level
  • BDTX $2.72
  • JJSF $119.24
  • Average True Range (ATR)
  • BDTX 0.17
  • JJSF 3.15
  • MACD
  • BDTX 0.03
  • JJSF 0.06
  • Stochastic Oscillator
  • BDTX 93.85
  • JJSF 24.07

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Share on Social Networks: